Evidence map›Paper›PMID 25611972›Full record

ArticlePloS one2015

Genetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study.

Elisa Boldrin, Enrica Rumiato, Matteo Fassan, Rocco Cappellesso, Massimo Rugge, Vanna Chiarion-Sileni, Alberto Ruol, Rita Alfieri, Matteo Cagol, Carlo Castoro and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Detection of Loss of Heterozygosity in cfDNA of AdvancedInternational journal of molecular sciences · 2019
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Elisa BoldrinImmunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Enrica RumiatoImmunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Matteo FassanDepartment of Medicine, Surgical Pathology and Cytopathology, University of Padova, Padova, Italy.
Rocco CappellessoDepartment of Medicine, Surgical Pathology and Cytopathology, University of Padova, Padova, Italy.
Massimo RuggeDepartment of Medicine, Surgical Pathology and Cytopathology, University of Padova, Padova, Italy.
Vanna Chiarion-SileniMedical Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Alberto RuolDepartment of Surgical Sciences, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Rita AlfieriOncological Surgery, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Matteo CagolOncological Surgery, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Carlo CastoroOncological Surgery, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Alberto AmadoriImmunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy; Department of Surgical Sciences, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Daniela SaggioroImmunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy.
Istituto Oncologico Veneto · ITUniversity of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDevelopment of novel therapeutic drugs and regimens for cancer treatment has led to improvements in patient long-term survival. This success has, however, been accompanied by the increased occurrence of second primary cancers. Indeed, patients who received regional radiotherapy for Hodgkin's Lymphoma (HL) or breast cancer may develop, many years later, a solid metachronous tumor in the irradiated field. Despite extensive epidemiological studies, little information is available on the genetic changes involved in the pathogenesis of these solid therapy-related neoplasms.

methodsUsing microsatellite markers located in 7 chromosomal regions frequently deleted in sporadic esophageal cancer, we investigated loss of heterozygosity (LOH) and microsatellite instability (MSI) in 46 paired (normal and tumor) samples. Twenty samples were of esophageal carcinoma developed in HL or breast cancer long-term survivors: 14 squamous cell carcinomas (ESCC) and 6 adenocarcinomas (EADC), while 26 samples, used as control, were of sporadic esophageal cancer (15 ESCC and 11 EADC).

resultsWe found that, though the overall LOH frequency at the studied chromosomal regions was similar among metachronous and sporadic tumors, the latter exhibited a statistically different higher LOH frequency at 17q21.31 (p = 0.018). By stratifying for tumor histotype we observed that LOH at 3p24.1, 5q11.2 and 9p21.3 were more frequent in ESCC than in EADC suggesting a different role of the genetic determinants located nearby these regions in the development of the two esophageal cancer histotypes.

conclusionsAltogether, our results strengthen the genetic diversity among ESCC and EADC whether they occurred spontaneously or after therapeutic treatments. The presence of histotype-specific alterations in esophageal carcinoma arisen in HL or breast cancer long-term survivors suggests that their transformation process, though the putative different etiological origin, may retrace sporadic ESCC and EADC carcinogenesis.

Indexed as

Loss of HeterozygosityMicrosatellite RepeatsSurvivorsAdenocarcinomaAdultAgedBreast NeoplasmsCarcinoma, Squamous CellEsophageal NeoplasmsFemaleHodgkin DiseaseHumansMaleMiddle AgedNeoplasms, Second Primary

Identifiers

PMID25611972
PMCPMC4303414
OpenAlexW1992479497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.